These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

820 related articles for article (PubMed ID: 11270595)

  • 1. Protective efficacy of rotavirus 2/6-virus-like particles combined with CT-E29H, a detoxified cholera toxin adjuvant.
    Siadat-Pajouh M; Cai L
    Viral Immunol; 2001; 14(1):31-47. PubMed ID: 11270595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rectal immunization with rotavirus virus-like particles induces systemic and mucosal humoral immune responses and protects mice against rotavirus infection.
    Parez N; Fourgeux C; Mohamed A; Dubuquoy C; Pillot M; Dehee A; Charpilienne A; Poncet D; Schwartz-Cornil I; Garbarg-Chenon A
    J Virol; 2006 Feb; 80(4):1752-61. PubMed ID: 16439532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrarectal immunization with rotavirus 2/6 virus-like particles induces an antirotavirus immune response localized in the intestinal mucosa and protects against rotavirus infection in mice.
    Agnello D; Hervé CA; Lavaux A; Darniot M; Guillon P; Charpilienne A; Pothier P
    J Virol; 2006 Apr; 80(8):3823-32. PubMed ID: 16571799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nasal immunization of mice with a rotavirus DNA vaccine that induces protective intestinal IgA antibodies.
    García-Díaz A; López-Andújar P; Rodríguez Díaz J; Montava R; Torres Barceló C; Ribes JM; Buesa J
    Vaccine; 2004 Dec; 23(4):489-98. PubMed ID: 15530697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a Bacillus subtilis-based rotavirus vaccine.
    Lee S; Belitsky BR; Brinker JP; Kerstein KO; Brown DW; Clements JD; Keusch GT; Tzipori S; Sonenshein AL; Herrmann JE
    Clin Vaccine Immunol; 2010 Nov; 17(11):1647-55. PubMed ID: 20810679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant.
    Choi AH; McNeal MM; Flint JA; Basu M; Lycke NY; Clements JD; Bean JA; Davis HL; McCluskie MJ; VanCott JL; Ward RL
    Vaccine; 2002 Mar; 20(13-14):1733-40. PubMed ID: 11906760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Particle-bombardment-mediated DNA vaccination with rotavirus VP4 or VP7 induces high levels of serum rotavirus IgG but fails to protect mice against challenge.
    Choi AH; Basu M; Rae MN; McNeal MM; Ward RL
    Virology; 1998 Oct; 250(1):230-40. PubMed ID: 9770437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rotavirus virus-like particles administered mucosally induce protective immunity.
    O'Neal CM; Crawford SE; Estes MK; Conner ME
    J Virol; 1997 Nov; 71(11):8707-17. PubMed ID: 9343229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection against rotavirus shedding after intranasal immunization of mice with a chimeric VP6 protein does not require intestinal IgA.
    McNeal MM; Stone SC; Basu M; Bean JA; Clements JD; Hendrickson BA; Choi AH; Ward RL
    Virology; 2006 Mar; 346(2):338-47. PubMed ID: 16375942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrarectal immunization of mice with VP6 and either LT(R192G) or CTA1-DD as adjuvant protects against fecal rotavirus shedding after EDIM challenge.
    McNeal MM; Basu M; Bean JA; Clements JD; Lycke NY; Ramne A; Löwenadler B; Choi AH; Ward RL
    Vaccine; 2007 Aug; 25(33):6224-31. PubMed ID: 17629371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Particle bombardment-mediated DNA vaccination with rotavirus VP6 induces high levels of serum rotavirus IgG but fails to protect mice against challenge.
    Choi AH; Knowlton DR; McNeal MM; Ward RL
    Virology; 1997 May; 232(1):129-38. PubMed ID: 9185596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice.
    Bertolotti-Ciarlet A; Ciarlet M; Crawford SE; Conner ME; Estes MK
    Vaccine; 2003 Sep; 21(25-26):3885-900. PubMed ID: 12922123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A modified cholera holotoxin CT-E29H enhances systemic and mucosal immune responses to recombinant Norwalk virus-virus like particle vaccine.
    Periwal SB; Kourie KR; Ramachandaran N; Blakeney SJ; DeBruin S; Zhu D; Zamb TJ; Smith L; Udem S; Eldridge JH; Shroff KE; Reilly PA
    Vaccine; 2003 Jan; 21(5-6):376-85. PubMed ID: 12531635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-independent protection against rotavirus infection of mice stimulated by intranasal immunization with chimeric VP4 or VP6 protein.
    Choi AH; Basu M; McNeal MM; Clements JD; Ward RL
    J Virol; 1999 Sep; 73(9):7574-81. PubMed ID: 10438847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral and intraperitoneal immunization with rotavirus 2/6 virus-like particles stimulates a systemic and mucosal immune response in mice.
    Shuttleworth G; Eckery DC; Awram P
    Arch Virol; 2005 Feb; 150(2):341-9. PubMed ID: 15578236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of rotavirus VP6 to DEC-205 induces protection against the infection in mice.
    Badillo-Godinez O; Gutierrez-Xicotencatl L; Plett-Torres T; Pedroza-Saavedra A; Gonzalez-Jaimes A; Chihu-Amparan L; Maldonado-Gama M; Espino-Solis G; Bonifaz LC; Esquivel-Guadarrama F
    Vaccine; 2015 Aug; 33(35):4228-37. PubMed ID: 25850020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune responses elicited against rotavirus middle layer protein VP6 inhibit viral replication in vitro and in vivo.
    Lappalainen S; Pastor AR; Tamminen K; López-Guerrero V; Esquivel-Guadarrama F; Palomares LA; Vesikari T; Blazevic V
    Hum Vaccin Immunother; 2014; 10(7):2039-47. PubMed ID: 25424814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal or oral immunization of inbred and outbred mice with murine or human rotavirus VP6 proteins protects against viral shedding after challenge with murine rotaviruses.
    Choi AH; McNeal MM; Basu M; Flint JA; Stone SC; Clements JD; Bean JA; Poe SA; VanCott JL; Ward RL
    Vaccine; 2002 Sep; 20(27-28):3310-21. PubMed ID: 12213401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Homotypic protection against rotavirus-induced diarrhea in infant mice breast-fed by dams immunized with the recombinant VP8* subunit of the VP4 capsid protein.
    Gil MT; de Souza CO; Asensi M; Buesa J
    Viral Immunol; 2000; 13(2):187-200. PubMed ID: 10892999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection against live rotavirus challenge in mice induced by parenteral and mucosal delivery of VP6 subunit rotavirus vaccine.
    Lappalainen S; Pastor AR; Malm M; López-Guerrero V; Esquivel-Guadarrama F; Palomares LA; Vesikari T; Blazevic V
    Arch Virol; 2015 Aug; 160(8):2075-8. PubMed ID: 26016444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.